TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) SEC Filings & Earnings Calls

Increased debt burden; potential refinancing risk if interest rates rise; no specific amounts disclosed to assess magnitude.

“Multiple supplemental indentures for euro and USD notes with maturities extending to 2037.”

Increased debt load but refinancing reduces near-term maturity risk.

“New notes have maturities from 2032 to 2037, replacing notes due 2027-2031.”

Geopolitical Conflict Disruption

“the conflict has disrupted critical global logistics corridors, maritime shipping routes, and air cargo hubs, including those used for the transportation of pharmaceutical products and key inputs.” · word for word

Tariff Impact on Supply Chain

“recent U.S. tariffs imposed, or threatened to be imposed, on materials and products from countries where we do business may impact our business.” · word for word

Generic Competition Pressure

“This decrease was mainly driven by lower revenues from lenalidomide capsules (a generic version of Revlimid®) due to increased generic competition in the U.S.” · word for word

AUSTEDO Price Negotiation Impact

“The revised prices set by the U.S. Government will become effective on January 1, 2027 and will apply to eligible Medicare patients.” · word for word

Generics revenue decline due to increased competition for lenalidomide capsules.

“Global generics revenues decreased by 15% YoY in LC, mainly due to lower revenues from lenalidomide capsules due to increased generic competition.” · word for word

Emalex acquisition expenses impacting near-term earnings.

“Expenses of $726 million for Emalex acquisition recorded in Q2 2026.”

Generic competition pressure on lenalidomide

“lower revenues from lenalidomide capsules (the generic version of Revlimid®) due to increased generic competition in the U.S.” · word for word

Geopolitical conflict impact on operations

“the conflict has disrupted critical global logistics corridors, maritime shipping routes, and air cargo hubs, including those used for the transportation of pharmaceutical products and key inputs” · word for word

U.S. government price setting for AUSTEDO

“Teva and the Centers for Medicare and Medicaid Services (“CMS”) negotiated a maximum fair price for AUSTEDO and AUSTEDO XR... The revised prices set by the U.S. Government will become effective on January 1, 2027” · word for word

Tariff exposure on global supply chain

“recent U.S. tariffs imposed, or threatened to be imposed, on materials and products from countries where we do business may impact our business” · word for word

Generic competition for lenalidomide capsules (Revlimid) pressuring generics revenue; expected to continue.

“lower revenues from lenalidomide capsules (the generic version of Revlimid) due to increased generic competition in the U.S.” · word for word

Emalex acquisition introduces $700M IPR&D charge and integration risk; regulatory approvals pending.

“impacted by an expected $700 million IPR&D charge and $75 million to reflect Emalex’s operating expenses and transaction-related expenses.” · word for word

Higher non-GAAP tax rate expected in 2026 (20-23% vs 15.8% in 2025) reducing net income.

“We expect our annual non-GAAP tax rate for 2026 to be between 20%-23%... higher than our non-GAAP tax rate for 2025, which was 15.8%.” · word for word

Opioid litigation liability

“Adjustments for legal settlements and loss contingencies in 2025 were mainly related to an update to the estimated settlement provision of $220 million for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments).” · word for word

Generic competition for COPAXONE

“Anticipated continued decline in COPAXONE® revenue from $503 million in 2024 to approximately $370 million in 2025, due to an expected increase in generic competition.” · word for word

Restructuring execution risk

“In 2025, Teva recorded $225 million of restructuring expenses primarily related to optimization activities in connection with Teva's Transformation programs related to Teva's global organization and operations, mainly through headcount reduction.” · word for word

IRA Price Negotiation on AUSTEDO

“During 2025, Teva and the Centers for Medicare and Medicaid Services ('CMS') negotiated a maximum fair price for AUSTEDO and AUSTEDO XR...The revised prices set by the U.S. Government will become effective January 1, 2027 and will apply to eligible Medicare patients.” · word for word

Generic Competition for Key Products

“AUSTEDO: 'We received notice letters from two ANDA filers...reached agreements with Lupin and Aurobindo...to sell their generic products beginning in April 2033, or earlier under certain circumstances.' BENDEKA: 'Hospira, Accord and DRL can launch their products on November 17, 2027, or earlier under certain circumstances.'”

High Debt Leverage

“As of December 31, 2025, we have consolidated debt of $16,807 million outstanding...The cash required to finance our interest and principal payment obligations under such debt reduces the cash available to fund our capital expenditures and grow our business.” · word for word

Geopolitical Risk (Israel/Middle East)

“Our corporate headquarters and a portion of our manufacturing activities are located in Israel...Ongoing military activity in the Middle East may result in disruption to our operations and facilities, such as our manufacturing and R&D facilities located in Israel.” · word for word

Opioid Litigation Settlement Payments

“The payments required to be made under this settlement agreement and others may have an adverse impact on our operations and cash flows and there is no assurance that we will have the liquidity or other resources necessary to make such payments.” · word for word

Foreign exchange volatility could negatively impact revenue and income.

“Volatile swings in FX can negatively impact revenue and income.” · word for word

Pipeline execution risk: multiple late-stage readouts in 2026; regulatory approvals needed for olanzapine LAI and other assets.

“2026 will be a milestone-rich year with multiple late-stage pipeline readouts; the anticipated FDA approval of olanzapine LAI.”

Generic competition and pricing pressure in generics segment.

“Generics portfolio stable: Increased by 2% in the U.S., decreased by 2% in Europe.” · word for word

Revenue expected flat to slightly down in 2026 vs 2025 (excluding duvakitug milestones).

“2026: Revenues flat to slightly down vs. 2025.”

Dependence on duvakitug milestones for additional 2025 contribution ($500M revenue, ~$400-430M EBITDA).

“Additional contribution from expected duvakitug milestones: Revenues $500M, Adjusted EBITDA ~$400M-$430M.”

AUSTEDO CMS price negotiation

“During the third quarter of 2025, Teva and the Centers for Medicare and Medicaid Services ('CMS') negotiated a maximum fair price for the AUSTEDO products... The revised prices set by the U.S. Government will become effective January 1, 2027 and will apply to eligible Medicare patients.” · word for word

Currency fluctuation exposure

“Fluctuations in the U.S. dollar versus other currencies in which we operate have in the past and may in the future materially impact our revenues, results of operations, profits and cash flows.” · word for word

U.S. tariff impact on supply chain

“Recent U.S. tariffs imposed or threatened to be imposed on materials and products from countries where we do business and any responsive or reciprocal actions taken by such countries could impact our costs and our global operations.” · word for word

TAPI sale process uncertainty; renewed sales process may face delays or lower valuation.

“Exclusive discussions with selected buyer on TAPI sale have terminated; Teva to initiate a renewed sales process.” · word for word

Europe and International Markets revenue decline; Japan BV divestiture impact.

“Europe segment decreased by 10% in LC; International Markets segment decreased by 10% in LC.”

Free cash flow decline in Q3 2025 vs Q3 2024 ($515M vs $922M) due to timing and legal settlements.

“free cash flow of $515 million...compared to $922 million in the third quarter of 2024.”